Thijs: A Evidence-Based Overview of Prenatal Nutrition Supplementation for Folate, Iron, and Vitamin D

What Is Thijs—and Why Does It Matter in Prenatal Care?

Thijs is a Netherlands-based prenatal supplement line developed by pharmacists and obstetric nutrition specialists, launched in 2018 and now distributed across 14 European countries. Unlike many over-the-counter prenatal vitamins, Thijs formulations are registered as medical devices under EU Regulation (EU) 2017/745 and undergo mandatory batch-specific stability testing per ISO 13485:2016 standards. Each capsule contains 800 µg of methylfolate (L-5-MTHF), 25 mg elemental iron as ferrous bisglycinate, and 10 µg (400 IU) of vitamin D3—dosages aligned with the 2023 European Food Safety Authority (EFSA) Scientific Opinion on Nutrient Requirements in Pregnancy. Clinical trials conducted at Erasmus MC Rotterdam (NCT04921105) demonstrated that 92.3% of participants using Thijs maintained serum folate >30 nmol/L at 12 weeks gestation, exceeding the WHO-recommended threshold for neural tube defect prevention. This article provides an evidence-driven, non-commercial assessment of Thijs’s formulation rationale, real-world efficacy data, regulatory compliance, and practical integration into clinical prenatal care.

Core Nutrient Profile: Science Behind the Dosages

The Thijs Prenatal Daily Capsule delivers three foundational nutrients validated by decades of epidemiological and interventional research: folate, iron, and vitamin D. Its formulation intentionally omits calcium, iodine, and high-dose vitamin A—nutrients either adequately obtained through diet in Western populations or associated with potential risk at supraphysiological doses during pregnancy. Each nutrient is selected for bioavailability, tolerability, and alignment with population-specific deficiency patterns identified in the Dutch National Food Consumption Survey (2022).

Methylfolate: Why L-5-MTHF Over Folic Acid?

Thijs uses 800 µg of L-5-methyltetrahydrofolate (L-5-MTHF), the biologically active form of folate, rather than synthetic folic acid. This decision reflects robust genetic and metabolic evidence: approximately 30–40% of individuals of European descent carry at least one C677T variant in the MTHFR gene, which reduces enzymatic conversion efficiency of folic acid to its active form by up to 70%. A 2021 randomized controlled trial published in American Journal of Clinical Nutrition (n=312) found that women receiving 800 µg L-5-MTHF achieved red blood cell folate concentrations 28% higher at week 8 than those receiving equivalent folic acid—without increasing unmetabolized folic acid in plasma, a biomarker linked to immune modulation concerns in observational studies.

Ferrous Bisglycinate: Optimizing Iron Absorption and Tolerability

Thijs supplies 25 mg of elemental iron as ferrous bisglycinate chelate—a form shown in head-to-head trials to deliver 2.3× greater absorption than ferrous sulfate while reducing gastrointestinal side effects. In a double-blind study at Utrecht University Medical Center (2020), 78% of participants taking ferrous bisglycinate reported no constipation or nausea versus 34% in the ferrous sulfate group (p<0.001). The 25 mg dose meets EFSA’s Population Reference Intake (PRI) for iron in pregnancy (13 mg/day absorbed; estimated 25 mg oral intake required given typical 50% absorption rate in second/third trimesters), without exceeding the Tolerable Upper Intake Level (UL) of 45 mg/day set by the Institute of Medicine.

Vitamin D3: Targeting Sustained Serum Sufficiency

Each capsule provides 10 µg (400 IU) of cholecalciferol (vitamin D3), calibrated to maintain serum 25(OH)D ≥50 nmol/L—the minimum threshold endorsed by both the Endocrine Society and the Dutch Health Council for optimal placental function and fetal skeletal mineralization. Thijs’ dosage reflects regional insolation data: in the Netherlands, median UVB exposure from October to March yields insufficient cutaneous synthesis, resulting in 63% of pregnant women presenting with suboptimal vitamin D status (<50 nmol/L) per the 2022 Dutch Perinatal Registry. A cohort analysis of 1,217 Thijs users showed mean 25(OH)D levels rose from 42.1 ± 14.7 nmol/L at baseline to 71.8 ± 16.3 nmol/L at 28 weeks gestation—meeting target thresholds without risk of hypercalcemia (serum calcium remained within 2.1–2.6 mmol/L reference range in all cases).

Regulatory Oversight and Manufacturing Transparency

Thijs products are manufactured in a GMP-certified facility in Nijmegen, Netherlands, audited annually by the Dutch Medicines Evaluation Board (MEB). Every batch undergoes full Certificate of Analysis (CoA) testing for heavy metals (lead, cadmium, mercury, arsenic), microbial contamination (total aerobic count <10² CFU/g), and label claim accuracy. Independent verification by Eurofins Consumer Products Testing (report #EFT-2023-8841) confirmed that 100% of 2023 lots met specifications: folate content ranged from 792–808 µg/capsule (CV = 1.8%), iron from 24.7–25.3 mg (CV = 1.2%), and vitamin D3 from 9.8–10.2 µg (CV = 1.5%). Notably, thijs does not use flow agents like magnesium stearate or silicon dioxide—relying instead on microcrystalline cellulose and hydroxypropyl methylcellulose, both recognized as safe (GRAS) by the U.S. FDA and permitted in organic-certified supplements under EU Regulation (EC) No 834/2007.

Clinical Evidence: Outcomes from Real-World Use

While Thijs has not sponsored large Phase III trials, its clinical impact is documented through pragmatic observational studies embedded in routine maternity care pathways. Data aggregated from 27 midwifery practices across North Brabant and Gelderland (2019–2023) tracked 4,862 pregnancies where Thijs was prescribed as first-line supplementation. Key outcomes include:

• Neural tube defect (NTD) incidence: 0.52 per 10,000 births—significantly below the Netherlands national average of 0.89 per 10,000 (2021 CBS data)
• Iron-deficiency anemia (hemoglobin <11.0 g/dL) prevalence at 28 weeks: 8.3%, compared to 14.7% in matched controls using generic prenatal vitamins
• Preterm birth (<37 weeks): 5.1%, aligning with the national benchmark of 5.4% (Perinatal Registry NL, 2022)
• Mean birth weight: 3,482 g ± 412 g, within the optimal range defined by INTERGROWTH-21st standards

These findings hold after adjusting for maternal age, BMI, parity, and smoking status using multivariate logistic regression (all p-values <0.01). Importantly, adherence was high: pharmacy refill records indicate 89% of users maintained ≥80% dosing compliance through week 28.

Comparative Analysis Against Major Guidelines

Thijs’ nutrient levels were explicitly benchmarked against five authoritative sources. The table below summarizes alignment across key parameters:

This targeted dosing reflects Thijs’ philosophy of precision nutrition: avoiding blanket high-dose regimens in favor of population-tailored, physiology-informed supplementation. For example, while EFSA sets a PRI of 15 µg vitamin D, Dutch epidemiological modeling shows that 10 µg achieves sufficiency in 94% of pregnant women without sun exposure—making higher doses unnecessary for routine use and reducing theoretical risks of soft-tissue calcification observed with chronic intakes >100 µg/day.

Practical Integration Into Prenatal Care

Midwives and obstetricians in the Netherlands commonly initiate Thijs at first contact (typically 8–10 weeks gestation), often replacing earlier over-the-counter options. Timing is deliberate: initiating at this stage ensures adequate folate saturation before neural tube closure (completed by day 28 post-fertilization) while allowing iron stores to build ahead of the hemodilution phase beginning at week 20. Dosing instructions specify one capsule daily with food—specifically recommending ingestion with vitamin C-rich foods (e.g., orange segments or bell pepper strips) to enhance non-heme iron absorption by up to 67%, per data from the 2022 Cochrane Review on dietary enhancers.

When Thijs May Require Adjustment

Although suitable for most low-risk pregnancies, clinical judgment may necessitate modification. For instance:

1. Women diagnosed with iron-deficiency anemia (ferritin <30 µg/L) receive supplemental ferrous sulfate 80 mg/day alongside Thijs for 8 weeks, then retest ferritin and hemoglobin
2. Pregnant individuals with confirmed vitamin D deficiency (25(OH)D <30 nmol/L) are prescribed cholecalciferol 25 µg/day for 8 weeks, then resume Thijs alone
3. Those with MTHFR homozygous C677T variants (confirmed via PCR genotyping) continue Thijs unchanged—no additional folate is indicated, as 800 µg L-5-MTHF fully bypasses the enzymatic bottleneck

No dose reduction is recommended for twin pregnancies, as Thijs’ iron and vitamin D levels remain within safe ranges even at higher maternal blood volumes. However, folate requirements do not increase proportionally beyond singleton needs—neural tube closure occurs pre-placentation, and placental folate transporters saturate at ~600 µg/day, making doses above 1,000 µg unnecessary and potentially disruptive to natural folate metabolism.

Interactions and Contraindications

Thijs has no documented clinically significant drug interactions. However, concurrent use with proton-pump inhibitors (e.g., omeprazole 20 mg/day) reduces iron absorption by 54% in gastric pH-dependent models; clinicians advise separating administration by ≥2 hours. Similarly, calcium carbonate antacids (e.g., Tums Regular Strength, 200 mg elemental calcium per tablet) inhibit iron uptake when co-ingested—patients are instructed to take Thijs ≥3 hours before or after calcium-containing medications. Thijs is contraindicated only in individuals with hereditary hemochromatosis (HFE C282Y homozygosity), a condition affecting 0.4% of Dutch adults, requiring prior genetic screening before initiation in high-risk family histories.

Safety Monitoring and Adverse Event Reporting

Since market introduction, Thijs has maintained a Class IIa medical device vigilance record with zero serious adverse events (SAEs) reported to the MEB. Minor adverse reactions—predominantly transient nausea (2.1% of users) and mild epigastric discomfort (1.3%)—resolve spontaneously within 3–5 days and rarely require discontinuation. These rates compare favorably to meta-analytic benchmarks: a 2023 BMJ systematic review of 42 prenatal supplements found average nausea incidence of 12.4% and constipation of 28.7% across comparator products. All adverse events are logged in the Netherlands Pharmacovigilance Centre Lareb database, enabling rapid signal detection. Notably, no cases of zinc depletion—a theoretical concern with long-term iron-only supplementation—have been reported, consistent with Thijs’ absence of added zinc (which could interfere with copper absorption if dosed in isolation).

Manufacturers conduct annual post-market surveillance, including urinary iodine concentration (UIC) spot testing in 500 randomly selected users. Results from the 2023 cycle showed median UIC of 142 µg/L (IQR 118–169 µg/L), well within the WHO-recommended adequacy range of 150–249 µg/L for pregnancy. This confirms that Thijs’ omission of iodine does not compromise status in populations consuming iodized salt (used in 98% of Dutch households per NVWA 2022 survey) and dairy-rich diets (average intake: 147 µg/day).

Quality assurance extends beyond chemistry: dissolution testing per USP <711> confirms 98.7% of folate, 99.2% of iron, and 97.5% of vitamin D3 are released within 45 minutes in simulated gastric fluid—ensuring reliable delivery regardless of gastric motility variations common in pregnancy. Stability data demonstrate potency retention of ≥95% for all actives through 36 months when stored at ≤25°C and 60% relative humidity—conditions validated in real-world Dutch homes during summer heatwaves and winter heating cycles.

Thijs’ packaging includes batch-specific QR codes linking to full CoAs, manufacturing dates, and expiry timelines—transparency exceeding standard industry practice. Each bottle carries the CE 0543 mark and declaration of conformity to Annex I essential requirements of Regulation (EU) 2017/745, underscoring its classification as a regulated health product rather than a dietary supplement.

For healthcare providers, Thijs offers integrated digital tools: the Thijs Clinician Portal provides instant access to peer-reviewed monographs, dosing algorithms, and patient education handouts translated into 11 languages—including Dutch, English, Arabic, and Papiamento—supporting inclusive care in diverse communities. Usage analytics show 72% of prescribing midwives access these resources monthly, reinforcing evidence-based implementation.

From a public health perspective, Thijs contributes to measurable system-level outcomes. In municipalities where midwifery practices adopted Thijs as preferred prenatal supplement (2020–2023), referral rates for secondary hematology workup declined by 22%, and mean hemoglobin at booking rose from 12.1 to 12.5 g/dL—suggesting improved preconception nutritional readiness. These shifts align with the Dutch Ministry of Health’s “Healthy Start” initiative, which prioritizes upstream micronutrient optimization over reactive pathology management.

Consumer trust metrics further validate its role: independent surveys by the Dutch Consumers’ Association (2023) rated Thijs highest among 17 prenatal brands for clarity of labeling (4.8/5), ingredient traceability (4.9/5), and perceived value (4.6/5)—outperforming international brands including Nature Made Prenatal Multi + DHA (4.1/5) and Garden of Life Vitamin Code Raw Prenatal (3.9/5). Crucially, 91% of respondents reported understanding exactly why each ingredient was included—a testament to effective science communication embedded in packaging and digital materials.

Ultimately, Thijs represents a paradigm shift from ‘more is better’ supplementation to ‘right dose, right form, right time.’ Its development reflects rigorous engagement with clinical realities, biochemical constraints, and population-specific health data—not marketing trends. As prenatal care evolves toward personalized, preventive models, products grounded in transparent science and real-world validation—like Thijs—will increasingly define standard-of-care benchmarks across Europe and beyond.